

Alex Furber;<sup>1</sup> Alison Martin<sup>1</sup>

<sup>1</sup> Crystallise Ltd alex.furber@crystallise.com, alison.martin@crystallise.com

## Objectives:

To create an Evidence Map of patient-reported outcome (PRO) studies of patients with non-Hodgkin's lymphoma, the geographical settings in which these studies were conducted, and the interventions assessed.

## Methods:

- The **heoro.com** database indexes publications available on PubMed according to study types, diseases, interventions and locations.
- We identified all PRO studies of non-Hodgkin's lymphoma published between 1960 and 6<sup>th</sup> April 2018 from the heoro.com database and indexed these by intervention, location, type of lymphoma, population, study methodology, disease stage and PRO tool used.
- The results are presented below as an Evidence Map.

## Results:

We identified 52 independent publications.


**Table 1:** Number of abstracts that specified treatment among a stated population type.

	Caregiver	Children	Patient	Survivor
Bendamustine	0	0	2	0
Bendamustine-rituximab	0	0	1	0
Chemotherapy	0	0	18	0
Denileukin diftitox	0	0	1	0
Epoetin	0	0	1	0
Filgrastim	0	0	1	0
Granisetron	0	0	1	0
Ibritumomab	0	0	1	0
Lenalidomide	0	0	2	0
None	1	1	12	5
Obinutuzumab	0	0	1	0
Psychosomatic therapy	0	0	1	0
Radiotherapy	0	0	3	0
Rituximab	0	0	8	0
SCT	0	0	5	1
Targeted	1	0	1	0
Tositumomab	0	0	2	0
Various	0	0	1	0
Vorinostat	0	0	1	0

**Table 2:** Number of PRO tools by disease type.

	B-cell	Cutaneous T-cell	DLBCL	Follicular	Hodgkin's	Mantle cell	NHL	Other	PCNSL
4DSQ	0	0	0	0	0	0	0	1	0
BFI	0	0	0	0	0	0	1	0	0
C-SGA	1	0	0	0	0	0	0	0	0
EORTC QLQ-C30	0	0	2	1	3	2	15	0	0
EORTC QLQ-STO22	0	0	1	0	0	0	0	0	0
EQ-5D	0	0	0	2	0	0	5	0	0
EQ-VAS	0	0	0	0	0	0	1	0	0
FACT-BR	0	0	0	0	0	0	0	0	1
FACT-G	0	1	0	0	0	0	3	0	0
FACT-Lym	0	0	0	0	0	0	2	0	0
FAHI	0	0	0	0	0	0	1	0	0
GDS-13	1	0	0	0	0	0	0	0	0
HADS	0	0	0	0	2	0	2	0	0
IOC	0	0	0	0	0	0	1	1	0
KS	0	0	0	0	0	0	0	0	1
LIP	0	0	0	0	0	0	1	0	0
MFI	0	0	0	0	1	0	2	0	0
MFI-20	0	0	0	0	0	0	1	0	0
MOS-SSS	0	0	0	0	0	0	1	0	0
NHL	0	0	0	0	0	0	0	1	0
OMDQ	0	0	0	0	0	0	1	0	0
PROMIS	0	0	0	0	0	0	1	0	0
PSI	0	0	0	0	0	0	0	0	1
PTGI	0	0	0	0	0	0	1	0	0
PTSDCC	0	0	0	0	0	0	1	0	0
PTSDIS	0	0	0	0	1	0	1	0	0
Q-TWiST	0	0	0	0	0	0	1	0	0
RSCL	0	0	0	0	0	0	2	0	0
SAS	0	0	0	0	0	0	0	0	1
SEIQoL-DW	0	0	0	0	0	0	1	0	0
SF-20	0	0	0	0	0	0	1	0	0
SF-36	0	0	0	0	1	0	5	1	0
SymQ	0	0	0	0	0	0	0	0	1
Unspecified	1	0	0	0	1	2	8	0	0
VAS	0	2	0	0	0	0	1	1	0
VES-13	1	0	0	0	0	0	0	0	0
VSHSS	0	0	0	0	0	0	1	0	0
WHO-OTS	0	0	0	0	0	0	1	0	0

**Figure 1:** Number of publications by geographical region



**Table 3:** Study methodology by date.

	1960:1999	2000:2004	2005:2009	2010:2014	2015:2018
Unallocated	0	0	0	0	0
Case-control	0	1	0	2	0
Clinical Trial	1	0	2	1	4
Cohort	0	1	2	2	3
Cohort study	0	0	0	0	2
Cross-sectional	0	1	1	2	0
Economic evaluation	0	0	0	1	1
Protocol	0	0	0	1	0
RCT	1	8	2	0	4
Review	0	1	0	0	0
SLR	0	0	0	1	1
Validation	2	2	0	3	1

## Conclusions:

PRO studies in non-Hodgkin's lymphoma have most commonly used the EORTC-QLQ-C30 to explore the use of traditional chemotherapy in a generic patient population. Most studies have been completed in the USA (13), Netherlands (9), Canada (7) and France (7). Although interest in NHL seemed to drop between 2005 and 2009, an upwards trend in published abstracts relating to NHL can be seen from 2010 to the present day, suggesting a renewed interest for the topic.

Download the free Evidence Map:



Crystallise Ltd, Unit 21 Thames Enterprise Centre, Thames Industrial Park, East Tilbury, Essex UK RM18 8RH Tel: +44 01375 488020

For a copy of this poster or the Evidence Map, email: [alison.martin@crystallise.com](mailto:alison.martin@crystallise.com)

[www.crystallise.com](http://www.crystallise.com) [www.heoro.com](http://www.heoro.com)

Presented at ISPOR EUROPE 2018  
November 10-14 2018; Barcelona, Spain